Communiqués Morepen Laboratories Limited NSE India S.E.

Actions

MOREPENLAB

INE083A01026

Produits pharmaceutiques

Temps Différé NSE India S.E. Autres places de cotation 13:05:09 25/06/2026			Varia. 5j.	Varia. 1 janv.
53,16 ^INR	+2,00 %		+4,17 %	+29,44 %

26/05	Morepen Laboratories Limited publie ses résultats pour le quatrième trimestre et l'exercice clos le 31 mars 2026	CI
26/05	Morepen Laboratories Limited recommande le versement d'un dividende final pour l'exercice clos le 31 mars 2026	CI

Communiqués

26/05	Morepen Laboratories : Audited Financial results for the quarter and financial year ended March 31, 2026 Unaudited financial results for the quarter and nine months ended December 31, 2025 Unaudited Financial results for the quarter and half year ended September 30, 2025 Unaudited Financial results for the quarter ended June 30, 2025	PU
17/04	Morepen Laboratories : Secures Fourth Consecutive USFDA Inspection with Zero Observations (NIL 483)	PU
23/02	Morepen Laboratories : Bags ₹825 Crore Global Deal; Expands Into High-Growth CDMO Segment.	PU
23/02	Morepen Laboratories : Bags ₹825 Crore Global Deal	PU
10/02	Morepen Laboratories : Q3'FY26 Presentation	PU
10/02	Morepen Laboratories : Unaudited financial results for the quarter and nine months ended December 31, 2025 Unaudited Financial results for the quarter and half year ended September 30, 2025 Unaudited Financial results for the quarter ended June 30, 2025	PU
17/11	Morepen Laboratories : Q2'FY26 Presentation	PU
14/11	Morepen Laboratories : Unaudited Financial results for the quarter and half year ended September 30, 2025 Unaudited Financial results for the quarter ended June 30, 2025	PU
06/08/25	Morepen Laboratories : Q1'FY26 Presentation	PU
06/08/25	Morepen Laboratories : Unaudited Financial results for the quarter ended June 30, 2025	PU
12/05/25	Morepen Laboratories : Audited Financial results for the quarter and financial year ended March 31, 2025	PU
12/05/25	Morepen Laboratories : Q4'FY25 Investor Presentation	PU
29/04/25	Morepen Laboratories : to Launch Resmetirom- a New Drug for Fatty Liver	PU
01/04/25	Morepen Laboratories : secures Loratadine approval for export to China	PU
18/03/25	New Launch: Empamore! Trusted, high-quality diabetes treatment—now at 90% lower cost!	PU
06/02/25	Morepen Laboratories : Unaudited Financial results for the quarter and nine months ended December 31, 2024 Unaudited Financial results for the quarter and half year ended September 30, 2024 Unaudited Financial results for the quarter ended June 30, 2024	PU
06/02/25	Morepen Laboratories : Investors Presentation Q3' FY 25	PU
12/11/24	Morepen Laboratories : Financial Results Q2 2024 25 Unaudited Financial results for the quarter and half year ended September 30, 2024 Unaudited Financial results for the quarter ended June 30, 2024	PU
11/11/24	Morepen Laboratories: Records 64% Jump in Net Profit in Q2’FY25	PU
11/11/24	Morepen Laboratories : Investors Presentation Q2' FY 25	PU
11/11/24	Morepen Laboratories : Unaudited Financial results for the quarter and half year ended September 30, 2024 Unaudited Financial results for the quarter ended June 30, 2024	PU
12/08/24	Morepen Laboratories : Unaudited Financial results for the quarter ended June 30, 2024 Outcome of the meeting of QIP Committee held on August 1, 2024	PU
12/08/24	Morepen Laboratories : Labs Q1 FY25 Profit Surges by 147%, Revenue Grows by 14%	PU
12/08/24	Morepen Laboratories : Q1' FY25 Investor presentation	PU
12/08/24	Morepen Laboratories : Final draft press release Q!'FY25 Morepen	PU